Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P79483
UPID:
DRB3_HUMAN
Alternative names:
MHC class II antigen DRB3
Alternative UPACC:
P79483; A0ZXY9; A7MA46; B5AU12; B5AU13; B5AU14; B8YAC6; C6H115; C6H116; O02875; O19590; O46701; O46794; O78049; O78162; P01913; P79663; Q29721; Q29809; Q2PPD0; Q30144; Q507L8; Q5SP44; Q5STE0; Q6YJU6; Q70M87; Q7YQ62; Q860I9; Q8SP69; Q8WLT7; Q8WLT8; Q95359; Q95HM8; Q95IE5; Q96H16; Q9BCP3; Q9BD18; Q9MYA4; Q9MYH3; Q9MYH4; Q9TP01; Q9TP02; Q9TPB5; Q9TQ21; Q9UIN3; Q9UIN5
Background:
The HLA class II histocompatibility antigen, DR beta 3 chain, known as MHC class II antigen DRB3, plays a pivotal role in the immune system. It presents antigenic peptides to CD4-positive T cells, guiding T-helper effector functions to eliminate infectious agents and transformed cells. This protein is crucial in presenting extracellular peptide antigens and peptides derived from intracellular proteins, highlighting its significance in immune surveillance and tolerance.
Therapeutic significance:
Understanding the role of HLA class II histocompatibility antigen, DR beta 3 chain, could open doors to potential therapeutic strategies. Its ability to present antigenic peptides from pathogens and tumors to CD4-positive T cells makes it a key player in developing vaccines and immunotherapies for infectious diseases, cancer, and autoimmune conditions.